Founded Year

2017

Stage

Series B | Alive

Total Raised

$65M

Last Raised

$50M | 2 mos ago

About Unlearn

Unlearn creates a machine learning (ML) platform for creating Intelligent Control Arms with Digital Twins. Unlearn is working closely with biopharma companies and regulators to ensure its methods meet scientific and regulatory standards.

Unlearn Headquarter Location

75 Hawthorne Street Suite 560

San Francisco, California, 94105,

United States

ESPs containing Unlearn

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTHMARKET STRENGTHLEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare / Biopharmaceuticals

Companies in this market enable virtual trials by testing drugs digitally on simulated versions of living entities. Solutions predict trial outcomes based on a number of different approaches, from using real-world data to simulating human physiology.

Unlearn named as Leader among 5 other companies, including Standigm, GNS Healthcare, and Novadiscovery.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Unlearn's Products & Differentiation

See Unlearn's products and how their products differentiate from alternatives and competitors

  • Digital Twins

    Digital Twins, or predicted outcomes generated from AI-based disease progression models, can be incorporated into clinical trials using PROCOVA* (Prognostic Covariate Adjustment) to increase power, decrease the number of patients receiving placebo, and reduce variability. *Please note that PROCOVA is not a separate product, but the statistical approach used to incorporate Digital Twins in clinical trials.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

Expert Collections containing Unlearn

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Unlearn is included in 9 Expert Collections, including Clinical Trials Tech.

C

Clinical Trials Tech

326 items

Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.

A

Artificial Intelligence

8,718 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

B

Biopharma Tech

5,567 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Conference Exhibitors

5,302 items

D

Digital Health 150

150 items

The winners of the second annual CB Insights Digital Health 150.

D

Digital Health

13,066 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

Unlearn Patents

Unlearn has filed 5 patents.

The 3 most popular patent topics include:

  • Artificial neural networks
  • Machine learning
  • Classification algorithms
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/1/2021

Regression analysis, Artificial neural networks, Machine learning, Design of experiments, Classification algorithms

Application

Application Date

12/1/2021

Grant Date

Title

Related Topics

Regression analysis, Artificial neural networks, Machine learning, Design of experiments, Classification algorithms

Status

Application

Latest Unlearn News

Unlearn Receives Draft Qualification Opinion from European Medicines Agency for Using the PROCOVA™ Framework to Implement TwinRCTs™

May 12, 2022

The three-step PROCOVA™ procedure provides a clear framework for implementing Unlearn’s TwinRCT™ solution to accelerate Phase 2 and Phase 3 clinical trials May 12, 2022 08:00 AM Eastern Daylight Time SAN FRANCISCO--( BUSINESS WIRE )--Unlearn®, developer of the first machine-learning technology that creates digital twins of patients in clinical trials to enable smaller, faster studies, today announced that the European Medicines Agency (EMA) recently released a draft qualification opinion providing a regulatory framework for the application of the company’s TwinRCT™ solution to Phase 2 and 3 clinical trials. The three-step PROCOVA™ procedure ( patent-pending ) is the foundation of Unlearn’s TwinRCT™ solution and describes how to use patient-specific prognostic scores derived from participants’ digital twins to run smaller clinical trials without introducing bias. “Unlearn has always taken a proactive approach to working with regulators in an effort to develop clear frameworks for how our digital twin approach can support clinical trials,” said Charles Fisher, PhD, founder and CEO of Unlearn. “The EMA’s draft opinion is a critically important milestone on this unique path for proactive regulatory qualification of our solution. Although pre-qualification of methods is not required, this ensures our partners can implement TwinRCTs™ in alignment with rigorous regulatory standards.” Unlearn works with pharmaceutical and biotechnology companies, as well as academic institutions, to optimize human clinical trials with TwinRCTs™. A TwinRCT™ is a randomized trial that uses historical control data and machine learning to achieve a higher probability of success with a smaller number of patients. Treatment effects for the primary and secondary outcomes can all be estimated with greater precision after correcting for each patient’s prognostic score derived from their digital twin. “I applaud the EMA for their commitment to creating clear guidance and pathways for cutting edge innovations to be introduced into clinical trials,” said Dr. Ann Taylor, former Chief Medical Officer of AstraZeneca and current Unlearn Board Member. “The Unlearn team has done an incredible job in not only developing a solution that will increase trial efficiency but also in providing the rigorous evidence suitable for supporting regulatory decisions.” For more information on the EMA draft qualification opinion, please visit Unlearn’s website to download a summary and a step-by-step guide for the practical application of PROCOVA™. About Unlearn Unlearn.AI is the only company creating TwinRCTs™, which combine AI, digital twins, and novel statistical methods to enable smaller, more efficient clinical trials. Unlearn’s technology has been published in conference abstracts and scientific journals, including Scientific Reports - Nature and The International Journal of Biostatistics. Unlearn is partnering with the world’s leading pharma companies, including Merck KGaA, Darmstadt, Germany, and continues to have discussions with regulators. The European Medicines Agency (EMA) published a draft qualification opinion for PROCOVA™ — a patent-pending method developed by Unlearn for leveraging historical data and machine learning to reduce sample sizes or increase power in Phase 2 or 3 clinical trials. For more information, please visit https://www.unlearn.ai or follow @UnlearnAI on Twitter, @unlearn-ai on LinkedIn. Contacts

  • When was Unlearn founded?

    Unlearn was founded in 2017.

  • Where is Unlearn's headquarters?

    Unlearn's headquarters is located at 75 Hawthorne Street, San Francisco.

  • What is Unlearn's latest funding round?

    Unlearn's latest funding round is Series B.

  • How much did Unlearn raise?

    Unlearn raised a total of $65M.

  • Who are the investors of Unlearn?

    Investors of Unlearn include Data Collective, 8VC, Mubadala Investment Company, Insight Partners, Radical Ventures and 5 more.

  • Who are Unlearn's competitors?

    Competitors of Unlearn include Owkin and 5 more.

  • What products does Unlearn offer?

    Unlearn's products include Digital Twins and 1 more.

You May Also Like

Holmusk Logo
Holmusk

Holmusk is a data science and digital therapeutics company with a global presence that is dedicated to establishing objective evidence as a core utility to the treatment of mental health and chronic diseases. Holmusk's proprietary technology powers data-driven medicine that leverages analytic and digital tools to address the unmet need in healthcare and pharma-life science.

Omada Health Logo
Omada Health

Omada Health is a digital behavioral medicine company that helps people to change the habits that put them most at risk for serious but largely preventable chronic conditions like heart disease and type 2 diabetes. The company brings behavioral counseling to anyone with an Internet connection, using insights about social networking, gaming, and behavioral science to motivate changes in lifestyle and deliver clinically-meaningful results.

4G Clinical Logo
4G Clinical

4G Clinical is a full-service RTSM company focused on simplifying and accelerating the drug development process. The company was founded to develop a service offering centered around a 4th generation Randomization and Trial Supply Management (RTSM) system, Prancer.

M
My Intelligent Machines

My Intelligent Machines is a platform as a service helping biologists analyze genomic data using AI. The platform finds the appropriate algorithms to analyze the user's data and generates text on its methods of analysis.

Steady Health Logo
Steady Health

Steady Health develops a digital platform specializing in daily glucose levels, nutrition and lifestyle.On June 4, 2021, Steady Health was acquired by Carbon Health. The terms of the transaction were not disclosed.

Levels Logo
Levels

Levels is a health and wellness company committed to advancing personalized health knowledge. Through data-driven discovery, science-backed education, and individualized insights, Levels motivates people to optimize their metabolic well-being. Levels was founded in 2019 and is based in New York, New York.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.